Biotron (ASX:BIT) has announced the acquisition of Sedarex, the owner of global patents for SedRx, a next-generation general anaesthetic with the potential to reshape the $6.5 billion global anaesthesia market. The deal is backed by a $2.5 million capital raising through a placement and rights offer, led by Peak Asset Management.
Biotron to acquire Sedarex and raise $2.5 million to accelerate anaesthetic program
October 15, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News

